Publications by authors named "J Neulen"
Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures.
Geburtshilfe Frauenheilkd
August 2023
The S3-guideline on endometrial cancer, first published in April 2018, was reviewed in its entirety between April 2020 and January 2022 and updated. The review was carried out at the request of German Cancer Aid as part of the Oncology Guidelines Program and the lead coordinators were the German Society for Gynecology and Obstetrics (DGGG), the Gynecology Oncology Working Group (AGO) of the German Cancer Society (DKG) and the German Cancer Aid (DKH). The guideline update was based on a systematic search and assessment of the literature published between 2016 and 2020.
View Article and Find Full Text PDFArticle Synopsis
- - The S3-guideline for endometrial cancer, initially released in April 2018, underwent a comprehensive review and update from April 2020 to January 2022, as requested by German Cancer Aid and coordinated by prominent gynecological and oncology organizations in Germany.
- - The update focused on integrating new evidence and refining recommendations to enhance treatment approaches, emphasizing personalized therapies to minimize unnecessary radical surgeries and non-beneficial adjuvant treatments for low-risk patients.
- - The revised guideline aims to optimize care for high-risk patients by clarifying the roles of radical surgery and additional treatments, ultimately improving survival rates and quality of life, while serving as a foundation for certified gynecological cancer centers.
Purpose: Despite considerable advances in recently developed combined oral contraceptives (COCs), resulting in lower rates of adverse events while maintaining contraceptive efficacy, there is interest in further innovation.
Materials And Methods: Estetrol (E4), a native oestrogen, and progestin drospirenone (DRSP) were combined in a new COC. A European expert panel reviewed the pharmacology, efficacy, and safety and tolerability of this combination.
A novel estetrol-containing combined oral contraceptive: European expert panel review.
Eur J Contracept Reprod Health Care
October 2022
Purpose: Despite considerable advances in recently developed combined oral contraceptives (COCs), resulting in lower rates of adverse events while maintaining contraceptive efficacy, there is interest in further innovation.
Materials And Methods: Estetrol (E4), a native oestrogen, and progestin drospirenone (DRSP) were combined in a new COC. A European expert panel reviewed the pharmacology, efficacy, and safety and tolerability of this combination.